Torrent has to its credit, leading brands in various therapeutic segments.

It is a dominant player
in the therapeutic areas of Cardiovascular (CV), Central Nervous System (CNS), Gastro-Intestinal,
Diabetology, Anti-infectives and Pain Management.

To sharpen its focus and enhance its customer reach in the domestic market, Torrent operates
throughsales and marketing divisions structured on specific Therapeutic areas. Currently, it has
15 sales and marketing divisions- Prima, Vista, Sparsh, Sensa, Mind, Axon, Neuron, Psycan CnD,
Psycan, Azuca, Delta, Oncology, B Well, Uno Spirit and Nephro each of which have a clear
therapeutic focus.

Recently, Torrent Pharma acquired the branded domestic formulations business of Elder
Pharmaceuticals in India and Nepal. The acquisition comprises a portfolio of 30 brands including
market-leading brands in the Women's Healthcare, Pain Management, Wound Care and
Nutraceuticals therapeutic segments. The transaction will also involve the transfer of employees
engaged in sales, marketing and operations of the India Business. Elder Pharma will continue to
manufacture & supply the products at its existing manufacturing facilities for Torrent Pharma for
a period of three years

United States of America ::

The worlds largest market for pharmaceuticals, USA, has always been on Torrent Pharmas strategic radar.
That intent has been converted in early 2004 into a concrete undertaking, a fully owned subsidiary called
Torrent Pharma Inc. This was floated to serve a large and growing need for high quality yet affordable
medicines in the USA.

Goal: To serve the large and growing need for cost-effective high quality medicines in the USA.

Business Opportunity: New to the USA market, Torrent Pharma is open to business opportunities at
various levels.

Marketing Collaborations: Torrent Pharma is open to collaborations with existing pharmaceutical

companies and suppliers to bring it closer to achieving its goal.

Partnerships: Torrent Pharma is well known for its R&D capabilities for AB and non-AB rated products. We
would be interested in partnerships which would help us commercialize our capabilities.

Research Collaborations: Torrent Pharma also conducts discovery research on metabolic disorders and
Vascular Diseases. Any opportunities for collaborations in this research field would be welcome.

Manufacturing Collaborations: The API and Formulation plants are approved by the European authorities
and have been inspected by a leading US regulatory consultant with respect to the USFDA. They and we are
confident that the plants will be approved by the USFDA once triggered. We would be open to mutually
beneficial manufacturing collaborations which would allow our partners to leverage our low cost position.

Adverse Event or Product Problem Reporting:

To report an adverse event or product complaint, please fill out this form. Provide as much information as
possible, including your contact information. If necessary, a Torrent representative may contact you to talk
further about your problem.

Latin America ::

Brazil: Torrent aims to penetrate the Latin American market with Brazil as the beachhead. Starting off in
September 2002, the Companys wholly owned subsidiary, Torrent do Brasil Ltda. (TDBL), with a current
investment of over US $ 7 million, has quickly picked up pace. The Company has already launched 19
products in the cardiovascular (CVS), central nervous system (CNS) and Oral Anti Diabetic segments.
These products are promoted to the doctors by a dedicated field force of more than 260 people. With the
recent launch of its products in the North & North Eastern states of the country, TDBL now covers the entire
geographical expanse of this vast & lucrative pharmaceutical market of Brazil through its network of over 200
distributors and pharmacy chains.

With a strong organizational set-up and a robust pipeline of new products, TDBL is today on a firm footing to
create value for its brands.

Russia & CIS ::

Torrent was one of the first and largest Indian suppliers of pharmaceutical formulations in Russia. One of
Torrents first international markets, it remains a key territory. The Companys brands enjoy an excellent
equity. Presently, there are 14 products in the Russian market with another 4 under registration. Torrent is
using Russia as the platform to register footholds in neighboring countries like Lithuania, Latvia, Estonia,
Ukraine etc.

Strategy: The emphasis is on brand building for prescription products, particularly in the cardiovascular
(CV), Central Nervous System (CNS) and Gastrointestinal (GI) segment and shifting the focus from tender-
based business to prescription-based business.

Europe ::

One of the most regulated and evolved worldwide, the EU market has been a veritable learning ground for
Torrent Pharma. With a presence spanning for more than a decade, we have adapted and developed along-
with the highly dynamic market conditions. Proven expertise in product development and strong regulatory
knowledge has helped us in developing a robust product portfolio of EU-GMP dossiers comprising of different
TAs including CNS, CVS, and GI among others.

At Torrent Pharma, we have always believed that in a dynamic market, partnership and alliances are of
utmost importance. It is because of this philosophy that today we are able to forge very strong tie-ups and
partnerships with global leaders like Novo Nordisk, Astra Zeneca and others.

Marketing footprints of Torrent Pharma can be seen in almost all the EU markets, especially because of our
strong and strategic licensing tie-ups with leading national companies along top Pan-European companies like
Teva, Mylan, Sandoz, Stada, and Orion among others.

We have strong presence across the continent by the virtue of our wholly owned subsidiaries in Germany, UK
and Romania and through our offices in Lithuania etc. We have strengthened our presence in Germany with
acquisition of Heumann Pharma Generics, a Pfizer group company. Heumanns product portfolio provides a
good strategic market position to Torrent Pharma in one of the biggest pharmaceutical markets in the globe.
These subsidiaries have given a very varied exposure, which would be beneficial and will help us in further
strengthening our position across EU.

est of the Word ::

The RoW (Rest of the World) market is an exciting assortment of more than 35 different markets entailing
South East Asia, Asia Pacific, Africa & Middle East. With the distinction between regulated and semi / non-
regulated market thinning by the day, Torrent today on the back of exemplary research initiatives has
developed capabilities of meeting regulatory requirements of different countries thus enhancing the
possibilities of offering its rich and diverse product portfolio to suit specific market requirements.

The strategy is two pronged, firstly to sustain and enhance sales growth by natural progression from a
trading based business model to a marketing based model with strong brand and corporate equity of existing
products and secondly to introduce and effectively position new molecules in all the markets to increase the
strength of our portfolio. Also, we continuously endeavor to identify and open up new markets thereby
increasing Torrent's territorial reach & catalyze our future growth. To support this initiative, more than 100
qualified and experienced professionals are placed in various markets to ensure the desired sales &
promotional efforts.

Moreover a conscious effort has been made to adopt novel business models in strategic markets. Opening
subsidiaries, plans to out license dossiers with supply tie up of formulations/ API's, & associate with global
players for collaborative research, marketing tie-ups and joint ventures to create synergies are on the anvil.

Africa: The vast, diverse and opportunistic African continent has been the focal point for Torrents
International Operations. The revenues have doubled since 1999-2000. With 355 product registrations
covering 14 countries, Torrent is consolidating its position in African Territories. Helped by a strong product
portfolio and a highly promising pipeline of pending product registrations, Torrent is well positioned to realize
the true potential of these markets.

The aim is to reach out to different territories in the African Continent by offering them pharmaceutical
products encompassing a wide range of therapeutic indications with impeccable quality at par with
International Standards.

Torrents focal areas of operations in Africa:

Zimbabwe

Kenya

Uganda

Nigeria

Ghana

South Africa

Asia: The largest continent of the world has maximum to offer when it comes to divergent opportunities.
Having already established in niche in the Indian market, Torrent today is firmly saddled to enhance its
operations and explore business possibilities covering wide geographical boundaries spanning Singapore,
Malaysia, Thailand, Philippines, Indonesia, Myanmar and Vietnam in eastern Asia to Yemen, Bahrain, Oman,
UAE and Saudi Arabia in the middle-east and Sri Lanka in South Asia.

Despite all these variations, what binds us uniformly to all these territories is the assurance to cater not only
the market per se, but the health and lifestyle of people. The strategy is to focus on high growth niche
products in Cardio Vascular, Neuropsychiatry & diabetalogy apart from making significant offerings in Gastro
Intestinal and Anti-Bacterial range.

Our major areas of operations:

Sri Lanka

Vietnam

Myanmar

Philippines

Malaysia

MENA: The current operations in Middle East North Africa are marked by its significance presence in Bahrain,
UAE, and Yemen . There are about 60 registrations in Kuwait, UAE, Yemen and Bahrain collectively and a
strong pipeline of products under registrations. Some of the key brands which have made there mark in
these two markets are Torsec, Nexpro IV, Deplatt, HB Plus, Omizac, Fegem, Topcef, and Quintor. Middle East
business is supported by a dedicated marketing set-up in Yemen and Bahrain.

Torrent is aggressively looking at expanding its operations in the MENA countries. The strategies are tailor
made to suit the market dynamics and hence varied for each market. With this in mind we have entered into
strategic tie-up in Saudi Arabia with a leading local player. Having received the approval of our manufacturing
facility from Saudi Arabia, Kuwait, Oman, Libya, our efforts have given due rewards. Similar activities are
underway to open key markets like Egypt, Tunisia, Syria, Jordan, Qatar, etc.

Australia: Our plans to enter the highly potential markets like Australia & New Zealand have received a
great boost with the TGA approval of our manufacturing facility. Torrent is in the process of establishing
partnerships & strategizing to leverage its strength in R&D to address these markets. We intend to adopt
business models in line with dynamics of these markets and are actively seeking partnership opportunities to
judiciously employ either one or a mix of the models listed below:

Out Licensing of dossiers / Technology Transfer with supply agreements.

Contract Manufacturing
 Strategic Alliances

United Kingdom ::

Torrent Pharma (UK) Ltd., the wholly owned subsidiary of Torrent Pharmaceuticals Ltd. was incorporated in
the year 2010 to explore business opportunities in the UK market. Torrent Pharma (UK) Ltd., has firmed up
strong plans to establish a strong footing in the UK market.